About
A brief description of who you are and what you do.
This section will only display on your public profile if you’ve added content.
You can update this in Pure (opens in a new tab). Select ‘Edit profile’. Under the heading and then ‘Curriculum and research description’, select ‘Add profile information’. In the dropdown menu, select - ‘About’.
Write about yourself in the third person. Aim for 100 to 150 words covering the main points about who you are and what you currently do. Clear, simple language is best. You can include specialist or technical terms.
You’ll be able to add details about your research, publications, career and academic history to other sections of your staff profile.
Research
Current research
Monoclonal antibodies (mAb) have become established in the treatment of a variety of malignancies - transforming patient outcomes. Despite this undoubted impact, responses remain variable and their mechanisms of action and of tumour resistance are controversial. The Beers research group is interested in how antibodies work to result in tumour regression. The research is currently focused on how the tumour microenvironment, particularly macrophages, affect effector function and how this could be manipulated to enhance antibody efficacy in patients. They have built a portfolio of complimentary models incorporating in vitro 3D modelling, appropriate in vivo model systems and primary clinical material.
1. Manipulating tumour microenvironment and effector function to enhance antibody therapy
Antibody immunotherapy relies predominantly on activatory Fc-gamma-Receptors (FcγR) expressing macrophages for effector function. However, tumour associated macrophages have a pro-tumour, anti-inflammatory phenotype associated with a poor prognosis and response to a variety of therapeutic interventions. The understanding of how macrophages are manipulated by tumours in vivo and how they may be re-programmed to augment mAb immunotherapy is a critical area of study where data is currently lacking.
2. How antibodies that directly target tumours induce therapeutic responses and may be augmented by other reagents
This area of research concerns a continuing interest, how monoclonal antibodies (mAb) achieve their therapeutic success. This concerns a variety of tumour targets and in particular the anti-CD20 mAb rituximab which is one of only a handful of mAb that have proven efficacious in the clinic. Our focus has been to delineate the key effector mechanisms employed by anti-CD20 mAb in vivo. Antibody mediated immunotherapy is purported to have three main mechanisms available for activity; complement dependent cytotoxicity, induction of programmed cell death and Fc:FcγR effector functions but we have recently demonstrated that only the latter is required for the depletion of normal B cells in vivo. We have found that some mAb lead to the internalisation of CD20 from the B cell surface and that this modulation has two concomitant effects; firstly it reduces effector cell mediated cell clearance and reduces the half-life of the antibodies in vivo. We have extended this work to encompass a range of lymphomas and found a correlation between internalisation and disease susceptibility to Rituximab therapy such that CD20 was rapidly internalised from the surface of most primary CLL (chronic lymphocytic leukaemia) and MCL (mantle cell lymphoma) cells, thus limiting engagement of anti-tumour effector mechanisms. Far less internalisation was observed in the majority of FL (follicular lymphoma) and DLBCL (diffuse large B cell lymphoma) samples, which may relate to their better clinical responses to rituximab.
3. The requirement for Fc receptors and effector cell interactions for immunomodulatory mAb
These antibodies represent a new and exciting branch of immunotherapy where the target cells for the therapy are not the tumour itself but effector cells of the innate and adaptive immune system. These mAb are able in this way to harness and redirect the powerful capabilities of the patient’s immune system to fight the cancer itself. We have found that the mAb isotype best able to elicit strong immunostimulatory signals and therapy differ markedly from that required for conventional targeted mAb therapy as typified by rituximab. Using a variety of models unique to Southampton we are currently dissecting the mechanisms and cells required for their activity and therapeutic efficacy.
The research group currently comprises; Dr Charles Birts, Against Breast Cancer Lecturer in Antibody Therapeutics (a joint appointment with Professor Max Crispin, Biological Sciences), four postdoctoral fellows, two research technicians, nine PhD students, and two clinical fellows.
Funding: Against Breast Cancer, Cancer Research UK, National Institutes for Health, Willberry’s Research
https://www.southampton.ac.uk/research/institutes-centres/centre-for-cancer-immunology
You can update the information for this section in Pure (opens in a new tab).
Research groups
Any research groups you belong to will automatically appear on your profile. Speak to your line manager if these are incorrect. Please do not raise a ticket in Ask HR.
Research interests
Add up to 5 research interests. The first 3 will appear in your staff profile next to your name. The full list will appear on your research page. Keep these brief and focus on the keywords people may use when searching for your work. Use a different line for each one.
In Pure (opens in a new tab), select ‘Edit profile’. Under the heading 'Curriculum and research description', select 'Add profile information'. In the dropdown menu, select 'Research interests: use separate lines'.
Current research
Update this in Pure (opens in a new tab). Select ‘Edit profile’ and then ‘Curriculum and research description - Current research’.
Describe your current research in 100 to 200 words. Write in the third person. Include broad key terms to help people discover your work, for example, “sustainability” or “fashion textiles”.
Research projects
Research Council funded projects will automatically appear here. The active project name is taken from the finance system.
Publications
Public outputs that list you as an author will appear here, once they’re validated by the ePrints Team. If you’re missing any outputs that you’ve added to Pure, they may be waiting for validation.
Supervision
Current PhD Students
Contact your Faculty Operating Service team to update PhD students you supervise and any you’ve previously supervised. Making this information available will help potential PhD applicants to find you.
Teaching
BM5. Immunology subject lead, lecturer and tutor on Year 1 and 2 Immunology Courses.
BIOL3037 and BIOL6038. Lecturer .
BMedSc/MMedSc. Provides laboratory based projects and research journal club tutorials. Offers 1-2 project placements that investigate direct targeting and immunomodulatory antibody therapy, tumour microenvironment and effector function.
Integrated PhD Cancer Pathway. Lecturer and tutor for ‘Host Immunity to Cancer’ and provides laboratory based research projects. Offers 1-2 project placements that investigate direct targeting and immunomodulatory antibody therapy, tumour microenvironment and effector function.
You can update your teaching description in Pure (opens in a new tab). Select ‘Edit profile’. Under the heading and then ‘Curriculum and research description’ , select ‘Add profile information’. In the dropdown menu, select – ‘Teaching Interests’. Describe your teaching interests and your current responsibilities. Aim for 200 words maximum.
Courses and modules
Contact the Curriculum and Quality Assurance (CQA) team for your faculty to update this section.
External roles and responsibilities
These are the public-facing activities you’d like people to know about.
This section will only display on your public profile if you’ve added content.
You can update your external roles and responsibilities in Pure (opens in a new tab). Select ‘+ Add content’ and then ‘Activity’, your ‘Personal’ tab and then ‘Activities’. Choose which activities you want to show on your public profile.
You can hide activities from your public profile. Set the visibility as 'Backend' to only show this information within Pure, or 'Confidential' to make it visible only to you.
Biography
Stephen Beers graduated from the University of Southampton in 1999 with a first class degree in Biochemistry. Subsequently he was awarded a personal PhD studentship from the BBSRC and graduated in 2003. He then moved to the Cancer Sciences Division (CSD) in the Faculty of Medicine and undertook his first postdoctoral fellowship in Immunochemistry and Immunotherapy. Following two successful postdoctoral positions he was awarded a career track fellowship and established his own group studying antibody effector function.
Prizes
- Nuffield Undergraduate Research Bursary (1997)
- Celltech Prize for best 2nd year Biochemistry Undergraduate (1998)
- Personal PhD award from BBSRC (1999)
- Career Track Fellowship award from Southampton University School of Medicine (2009)
- 14th ICI World Immunology Congress (oral presentation) (2010)
- Research Prize 2010 - Postdoctoral Association Conference (prize awarded for the best research paper produced by a post-doc in the School) (2010)
- Elected by ballot by Federation of American Societies for Experimental Biology (FASEB) Science Research Conference delegates to organise next two ‘Immunoreceptors and Immunotherapy’ conferences in 2018 and 2020 (2016)
You can update your biography section in Pure (opens in a new tab). Select your ‘Personal’ tab then ‘Edit profile’. Under the heading, and ‘Curriculum and research description’, select ‘Add profile information’. In the dropdown menu, select - ‘Biography’. Aim for no more than 400 words.
This section will only appear if you enter the information into Pure (opens in a new tab).
Prizes
You can update this section in Pure (opens in a new tab). Select ‘+Add content’ and then ‘Prize’. using the ‘Prizes’ section.
You can choose to hide prizes from your public profile. Set the visibility as ‘Backend’ to only show this information within Pure, or ‘Confidential’ to make it visible only to you.